---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-056278"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:57:34.902549+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Organon Q1 revenue $1.567B (+8% ex-FX); adj. EPS $1.65; reaffirms FY guidance

## Summary
- Revenue $1,567M, +4% as-reported / +8% ex-FX vs Q1 2021; Women's Health -5%, Biosimilars +22%, Established Brands +10%.
- Net income from cont. ops $348M ($1.36 diluted EPS); adjusted net income $420M ($1.65 adj. diluted EPS).
- Adjusted EBITDA $647M; gross margin 64.2% (adj. 66.5%); board declares $0.28 quarterly dividend.
- Full year 2022 financial guidance reaffirmed; acquired rights to Marvelon/Mercilon and Xaciato license in certain markets.

## SEC filing metadata
- accession: 0001104659-22-056278
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465922056278/0001104659-22-056278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465922056278/tm2214364d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-056278
- JSON: https://secwatch.observer/filing/0001104659-22-056278.json
- Plain text: https://secwatch.observer/filing/0001104659-22-056278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.